Want to join the conversation?
$HOLX's 2Q16 total revenue grew 5.8% on a reported basis or 6.3% in constant currency, and excluding the headwind from discontinued products revenue would have grown 7% plus in constant currency. Non-GAAP GM was 65.8% in 2Q16, up 240 BP versus 2Q15. Non-GAAP operating margin increased to 33.9% in the quarter, 40 BP higher than 2Q15.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.